X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bora Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2024
Details:
Tapazole-Generic (methimazole) is a thyroid peroxidase inhibitor, small molecule drug candidate which is indicated for the treatment of Graves’ disease with hyperthyroidism or toxic multinodular goiter.
Lead Product(s): Methimazole
Therapeutic Area: Endocrinology Product Name: Tapazole-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2024
Details:
Through the acquisition, Bora gains Upsher-Smith’s product portfolio, including Amantadine hydrochloride, indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bora Pharmaceuticals
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024
Details:
Pitavastatin tablet is a HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in Adult patients with primary hyperlipidemia or mixed dyslipidemia.
Lead Product(s): Pitavastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Livalo-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Mesalamine, also known as 5-aminosalicylic acid extended-release capsule is a small molecule, which is indicated for the maintenance of remission of ulcerative colitis in adults.
Lead Product(s): Mesalazine
Therapeutic Area: Gastroenterology Product Name: Apriso-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
Isotretinoin capsule inhibits sebaceous gland function and keratinization at pharmacologic doses. It is being indicated for the treatment of severe recalcitrant nodular acne.
Lead Product(s): Isotretinoin
Therapeutic Area: Dermatology Product Name: Accutane-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.
Lead Product(s): Sumatriptan
Therapeutic Area: Neurology Product Name: Zembrace SymTouch
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: $25.0 million Upfront Cash: $22.0 million
Deal Type: Acquisition July 03, 2023
Details:
The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.
Lead Product(s): Sumatriptan
Therapeutic Area: Neurology Product Name: Zembrace SymTouch
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: $25.0 million Upfront Cash: $22.0 million
Deal Type: Acquisition June 26, 2023
Details:
Fluphenazine hydrochloride Tablets are a generic version of the brand product, Prolixin. Company has launched Fluphenazine Hydrochloride Tablets, USP in four strengths, 1 mg, 2.5 mg, 5 mg, and 10 mg.
Lead Product(s): Fluphenazine
Therapeutic Area: Psychiatry/Psychology Product Name: Prolixin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Dicyclomine hydrochloride is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.
Lead Product(s): Dicyclomine Hydrochloride
Therapeutic Area: Gastroenterology Product Name: Dicyclomine Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
